FOI 7274 - Breast Cancer Treatment
Date: 26 April 2022 to 26 April 2025
Q1. In the past 3 months (or the latest 3 months data you have available), how many Metastatic/advanced Breast cancer patients were treated with:
- Abemaciclib (Verzenios) + aromatase inhibitor *
- Abemaciclib (Verzenios) + Fulvestrant (Faslodex)
- Alpelisib (Piqray) + Fulvestrant (Faslodex)
- Atezolizumab (Tecentriq)**
- Bevacizumab (Avastin)
- Eribulin (Halaven)
- Everolimus (Afinitor) + Exemestane
- Fulvestrant (Faslodex) as a single agent
- Gemcitabine + paclitaxel
- Herceptin (Trastuzumab) + paclitaxel
- Herceptin (Trastuzumab) as a single agent
- Lapatinib (Tyverb)
- Neratinib (Nerlynx)
- Olaparib (Lynparza)
- Palbociclib (Ibrance) + aromatase inhibitor*
- Palbociclib (Ibrance) + Fulvestrant (Faslodex)
- Pertuzumab (Perjeta) + trastuzumab + docetaxel
- Ribociclib (Kisqali) + aromatase inhibitor*
- Ribociclib (Kisqali) + Fulvestrant (Faslodex)
- Talazoparib (Talzenna)
- Trastuzumab emtansine (Kadcyla)
- Other active systemic anti-cancer therapy **
*aromatase inhibitor eg. Anastrozole, Exemestane or Letrozole
**eg. docetaxel, vinorelbine or capecitabine as a single agent
Q2. For the above patients, how many of these received their first ever dose for each product line?
- Request ID:7274
- Category:Clinical - Drugs
- Response:
April 2022
Q1. In the past 3 months (or the latest 3 months data you have available), how many Metastatic/advanced Breast cancer patients were treated with:
- Abemaciclib (Verzenios) + aromatase inhibitor *
- Abemaciclib (Verzenios) + Fulvestrant (Faslodex)
- Alpelisib (Piqray) + Fulvestrant (Faslodex)
- Atezolizumab (Tecentriq)**
- Bevacizumab (Avastin)
- Eribulin (Halaven)
- Everolimus (Afinitor) + Exemestane
- Fulvestrant (Faslodex) as a single agent
- Gemcitabine + paclitaxel
- Herceptin (Trastuzumab) + paclitaxel
- Herceptin (Trastuzumab) as a single agent
- Lapatinib (Tyverb)
- Neratinib (Nerlynx)
- Olaparib (Lynparza)
- Palbociclib (Ibrance) + aromatase inhibitor*
- Palbociclib (Ibrance) + Fulvestrant (Faslodex)
- Pertuzumab (Perjeta) + trastuzumab + docetaxel
- Ribociclib (Kisqali) + aromatase inhibitor*
- Ribociclib (Kisqali) + Fulvestrant (Faslodex)
- Talazoparib (Talzenna)
- Trastuzumab emtansine (Kadcyla)
- Other active systemic anti-cancer therapy **
*aromatase inhibitor eg. Anastrozole, Exemestane or Letrozole
**eg. docetaxel, vinorelbine or capecitabine as a single agent
*Please see below.
Q2. For the above patients, how many of these received their first ever dose for each product line?
The Trust regret this data is not collated.
*Medway NHS Foundation Trust regret that we are unable to answer this question. This is because the Trust’s Pharmacy department can provide data on the number of patients that were issued each drug, but their records do not show the indication that each drug was prescribed for. Please see below pharmacy data for the reporting period 01/01/2022 to 31/03/2022 for the BNF Category: Immune System & Malignant Disease (Chapter 8). Please note, that if the drug is not listed, it is because it has not been issued. Where the number is less than five, this has been marked as <5.
Drug Name
Total Number of Patients
CALCIUM FOLINATE (ORAL)
<5
ABEMACICLIB (VERZENIOS)
<5
ABIRATERONE
18
ABIRATERONE (ZYTIGA) - HOMECARE
7
ACALABRUTINIB (CALQUENCE)
<5
ACALABRUTINIB (CALQUENCE) - HOMECARE
14
AFATINIB (ORAL)
<5
ALECTINIB
<5
ANASTROZOLE (ORAL)
<5
APALUTIMIDE (ERLEADA)
<5
ATEZOLIZUMAB (TECENTRIQ)
13
AVELUMAB (BAVENCIO)
6
AXITINIB (ORAL)
7
AZACITIDINE
13
AZATHIOPRINE
16
BCG FOR INTRADERMAL USE
<5
BCG FOR INTRAVESICAL USE (OncoTICE)
40
BENDAMUSTINE
<5
BICALUTAMIDE
24
BLEOMYCIN
<5
BORTEZOMIB
20
BOSUTINIB (BOSULIF) - HOMECARE
6
BRENTUXIMAB
<5
CABAZITAXEL
<5
CABOZANTINIB
<5
CABOZANTINIB (CABOMETYX)
<5
CALCIUM FOLINATE (IV)
53
CAPECITABINE (ORAL)
47
CARBOPLATIN (IV)
61
CARFILZOMIB
<5
CETUXIMAB
7
CHLORAMBUCIL
<5
CICLOSPORIN (DEXIMUNE)
<5
CICLOSPORIN (NEORAL)
<5
CISPLATIN (IV)
7
CYCLOPHOSPHAMIDE (IV)
83
CYCLOPHOSPHAMIDE (ORAL)
6
CYTARABINE
6
DACARBAZINE
<5
DARATUMUMAB (DARZALEX)
11
DASATINIB
<5
DASATINIB (SPRYCEL) - HOMECARE
6
DAUNORUBICIN
<5
DEXRAZOXANE (SAVENE)
<5
DIETHYLSTILBESTROL (STILBOESTROL)
<5
DIMETHYL FUMARATE (TECIFIDERA) - HOMECARE
103
DIMETHYL SULFOXIDE (DMSO)
<5
DOCETAXEL
30
DOXORUBICIN
25
ENTRECTINIB (ROZLYTREK)
<5
ENZALUTAMIDE
42
ENZALUTAMIDE (XTANDI) - HOMECARE
20
EPIRUBICIN
52
ERIBULIN
<5
ETOPOSIDE
15
EVEROLIMUS
<5
EXEMESTANE
<5
FLUDARABINE (IV)
<5
FLUOROURACIL
54
FULVESTRANT
10
GEMCITABINE
14
GEMTUZUMAB, OZOGAMICIN, MYLOTARG
<5
GILTERITINIB (XOSPATA) - HOMECARE
<5
GLATIRAMER ACETATE (COPAXONE) - HOMECARE
8
HYDROXYCARBAMIDE
49
HYDROXYCARBAMIDE - HOMECARE
<5
HYDROXYCARBAMIDE (SIKLOS)
<5
HYDROXYCARBAMIDE (XROMI)
<5
IBRUTINIB
<5
IBRUTINIB - HOMECARE
<5
IBRUTINIB (IMBRUVICA) - HOMECARE
13
IDELALISIB
<5
IDELALISIB (ZYDELIG) - HOMECARE
<5
IMATINIB
<5
IMATINIB - HOMECARE
7
INTERFERON BETA 1A (AVONEX) - HOMECARE
25
INTERFERON BETA-1a (REBIF via REBISMART) - HOMECARE
16
INTERFERON BETA-1b (BETAFERON 250mcg/ml) - HOMECARE
<5
IPILIMUMAB (YERVOY)
<5
IRINOTECAN
31
ISATUXIMAB (SARCLISA)
<5
IXAZOMIB (NINLARO)
<5
IXAZOMIB (NINLARO) - HOMECARE
9
LENALIDAMIDE - HOMECARE
39
LENALIDOMIDE
7
LETROZOLE
50
LETROZOLE - HOMECARE
<5
LEUPRORELIN
<5
LORLATINIB (LORVIQUA)
<5
MELPHALAN
<5
MERCAPTOPURINE
<5
MESNA
6
METHOTREXATE
<5
METHOTREXATE (IV)
<5
METHOTREXATE (METOJECT PEN)
16
METHOTREXATE (METOJECT PEN) - HOMECARE
209
METHOTREXATE (ORAL)
100
MITOMYCIN
9
MYCOPHENOLATE MOFETIL
16
MYCOPHENOLIC ACID (ORAL)
<5
NATALIZUMAB
16
NILOTINIB (TASIGNA) - HOMECARE
12
NINTEDANIB
<5
NIVOLUMAB (OPDIVO)
10
OBINUTUZUMAB
10
OCTREOTIDE
<5
OSIMERTINIB
<5
OXALIPLATIN (IV)
41
PACLITAXEL
60
PALBOCICLIB
36
PALBOCICLIB (IBRANCE) - HOMECARE
<5
PANOBINOSTAT
<5
PAZOPANIB
11
PAZOPANIB (VOTRIENT) - HOMECARE
<5
PEMBROLIZUMAB
39
PEMETREXTED
23
PERTUZUMAB
<5
PERTUZUMAB/TRASTUZUMAB (PHESGO)
39
POLATUZUMAB (POLIVY)
<5
POMALIDOMIDE
<5
POMALIDOMIDE (IMNOVID) - HOMECARE
<5
PONATINIB - HOMECARE
<5
RALTITREXED
<5
RASBURICASE
<5
RIBOCICLIB
<5
RITUXIMAB (MABTHERA)
13
RITUXIMAB (RIXATHON)
7
RITUXIMAB (TRUXIMA)
38
RUXOLITINIB
<5
RUXOLITINIB - HOMECARE
13
SUNITINIB
<5
TACROLIMUS
<5
TACROLIMUS (ADOPORT)
<5
TACROLIMUS (ADVAGRAF)
<5
TACROLIMUS (PROGRAF)
<5
TACROLIMUS (TOPICAL)
<5
TAMOXIFEN
12
TERIFLUNOMIDE (AUBAGIO) - HOMECARE
42
THALIDOMIDE
11
TIPIRACIL/TRIFLURIDINE
7
TOPOTECAN
<5
TRASTUZUMAB
<5
TRASTUZUMAB (HERCEPTIN)
18
TRASTUZUMAB (ONTRUZANT)
6
TRASTUZUMAB DERUXTECAN
10
TRASTUZUMAB EMTANSINE
13
VENETOCLAX
9
VENETOCLAX (VENCLYXTO) - HOMECARE
<5
VINBLASTINE
<5
VINCRISTINE
38
VINORELBINE
10
